全文获取类型
收费全文 | 14403篇 |
免费 | 1084篇 |
国内免费 | 28篇 |
专业分类
耳鼻咽喉 | 108篇 |
儿科学 | 437篇 |
妇产科学 | 377篇 |
基础医学 | 2365篇 |
口腔科学 | 282篇 |
临床医学 | 1645篇 |
内科学 | 2758篇 |
皮肤病学 | 341篇 |
神经病学 | 1526篇 |
特种医学 | 516篇 |
外科学 | 1633篇 |
综合类 | 115篇 |
一般理论 | 14篇 |
预防医学 | 1260篇 |
眼科学 | 201篇 |
药学 | 850篇 |
中国医学 | 18篇 |
肿瘤学 | 1069篇 |
出版年
2023年 | 132篇 |
2022年 | 94篇 |
2021年 | 295篇 |
2020年 | 302篇 |
2019年 | 423篇 |
2018年 | 430篇 |
2017年 | 360篇 |
2016年 | 415篇 |
2015年 | 393篇 |
2014年 | 513篇 |
2013年 | 729篇 |
2012年 | 1029篇 |
2011年 | 963篇 |
2010年 | 504篇 |
2009年 | 501篇 |
2008年 | 777篇 |
2007年 | 820篇 |
2006年 | 776篇 |
2005年 | 715篇 |
2004年 | 621篇 |
2003年 | 582篇 |
2002年 | 562篇 |
2001年 | 305篇 |
2000年 | 299篇 |
1999年 | 277篇 |
1998年 | 136篇 |
1997年 | 85篇 |
1996年 | 86篇 |
1995年 | 78篇 |
1994年 | 87篇 |
1993年 | 74篇 |
1992年 | 192篇 |
1991年 | 159篇 |
1990年 | 141篇 |
1989年 | 162篇 |
1988年 | 130篇 |
1987年 | 128篇 |
1986年 | 113篇 |
1985年 | 115篇 |
1984年 | 100篇 |
1983年 | 77篇 |
1982年 | 55篇 |
1981年 | 51篇 |
1980年 | 39篇 |
1979年 | 72篇 |
1978年 | 37篇 |
1977年 | 51篇 |
1974年 | 45篇 |
1973年 | 38篇 |
1971年 | 37篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Heramvand Nadia Masyuk Maryna Muessig Johanna M. Nia Amir M. Karathanos Athanasios Polzin Amin Valgimigli Marco Gurbel Paul A. Tantry Udaya S. Kelm Malte Jung Christian 《Journal of thrombosis and thrombolysis》2022,54(2):301-308
Journal of Thrombosis and Thrombolysis - Tirofiban is a glycoproteine (GP) IIb/IIIa receptor antagonist, which inhibits platelet-platelet aggregation and is a potential adjunctive antithrombotic... 相似文献
2.
3.
Huebner Lucas Schroeder Ines Kraft Eduard Gutmann Marcus Biebl Johanna Klamt Amrei Christin Frey Jana Warmbein Angelika Rathgeber Ivanka Eberl Inge Fischer Uli Scharf Christina Schaller Stefan J. Zoller Michael 《Der Anaesthesist》2022,71(10):795-800
Die Anaesthesiologie - Bei etwa 43?% aller Überlebenden der Intensivmedizin wird ein erworbenes Syndrom an Muskelschwäche beobachtet, welches Überleben und Lebensqualität... 相似文献
4.
5.
Babchenko V. Ya. Belova A. S. Bashirzade A. A. Tikhonova M. A. Demin K. A. Zabegalov K. N. Petersen E. V. Kalueff A. V. Amstislavskaya T. G. 《Neuroscience and behavioral physiology》2022,52(3):405-414
Neuroscience and Behavioral Physiology - Current medicine has a high level of interest in studies of the pathogenesis of traumatic brain injury (TBI). This comes particularly from high levels of... 相似文献
6.
Leonie Konczalla Daniel R. Perez Nadine Wenzel Gerrit Wolters-Eisfeld Clarissa Klemp Johanna Lüddeke Annika Wolski Dirk Landschulze Chris Meier Anika Buchholz Dichao Yao Bianca T. Hofmann Julia K. Graß Sarah L. Spriestersbach Katharina Grupp Udo Schumacher Christian Betzel Svetlana Kapis Theresa Nuguid Pablo Steinberg Klaus Püschel Guido Sauter Maximillian Bockhorn Faik G. Uzunoglu Jakob R. Izbicki Cenap Güngör Alexander T. El Gammal 《International journal of cancer. Journal international du cancer》2020,146(6):1618-1630
MALT1 is a key mediator of NF-κB signaling and a main driver of B-cell lymphomas. Remarkably, MALT1 is expressed in the majority of pancreatic ductal adenocarcinomas (PDACs) as well, but absent from normal exocrine pancreatic tissue. Following, MALT1 shows off to be a specific target in cancer cells of PDAC without affecting regular pancreatic cells. Therefore, we studied the impact of pharmacological MALT1 inhibition in pancreatic cancer and showed promising effects on tumor progression. Mepazine (Mep), a phenothiazine derivative, is a known potent MALT1 inhibitor. Newly, we described that biperiden (Bip) is a potent MALT1 inhibitor with even less pharmacological side effects. Thus, Bip is a promising drug leading to reduced proliferation and increased apoptosis in PDAC cells in vitro and in vivo. By compromising MALT1 activity, nuclear translocation of c-Rel is prevented. c-Rel is critical for NF-κB-dependent inhibition of apoptosis. Hence, off-label use of Bip or Mep represents a promising new therapeutic approach to PDAC treatment. Regularly, the Anticholinergicum Bip is used to treat neurological side effects of Phenothiazines, like extrapyramidal symptoms. 相似文献
7.
8.
9.
Kwun Lam Anneli Peolsson Emiliano Soldini Hkan Lfgren Johanna Wibault sa Dedering Birgitta
berg Peter Zsigmond Marco Barbero Deborah Falla 《Medicine》2021,100(8)
Pain as a result of cervical radiculopathy (CR) can be widespread, nondermatomal and individually specific, but the association between pain extent and other clinical features has never been explored. The objective of this study is to investigate whether pain extent relates to clinical variables including pain intensity in addition to health indicators including disability, general health, depression, somatic anxiety, coping strategies or self-efficacy.An observational cohort study was conducted. Participants were recruited from 4 hospital spinal centres in Sweden. Pain extent was quantified from the pain drawings of 190 individuals with cervical disc disease, verified with magnetic resonance imaging (MRI) and compatible with clinical findings (examined by a neurosurgeon), that show cervical nerve root compression. Pain extent was evaluated in relation to neck pain, arm pain, and headache intensity. Multiple linear regression analysis were then used to verify whether pain extent was associated with other health indicators including disability, health-related quality of life, depression, somatic anxiety, coping strategies and self-efficacy.Pain extent was directly related to neck, arm and headache pain intensity (all P < .01). Multiple linear regression revealed that pain extent was significantly associated only to the level of perceived disability (P < .01).Increased pain extent in people with CR is associated with higher headache, neck and arm pain intensity, and disability but not measures of general health, depression, somatic anxiety, coping strategies or self-efficacy. 相似文献
10.
Kristina S. Petersen Sarah Rae Erik Venos Daniela Malta Kathy Trieu Joseph Alvin Santos Sudhir Raj Thout Jacqui Webster Norm R. C. Campbell JoAnne Arcand 《Journal of clinical hypertension (Greenwich, Conn.)》2019,21(2):307-323
The purpose of this review is to identify, summarize, and critically appraise studies on dietary salt and health outcomes that were published from April 2017 to March 2018. The search strategy was adapted from a previous systematic review on dietary salt and health. Identified studies were screened based on a priori defined criteria to identify publications eligible for detailed critical appraisals. Overall, 6747 citations were identified by the search strategy, and 42 health outcome studies were identified. Three of the 42 studies met the criteria for methodological quality and health outcomes and underwent detailed critical appraisals and commentary. In addition, a systematic review and meta‐analysis was critically appraised, although it did not strictly meet our methodological criteria. All four of the studies critically appraised found that sodium reduction improved blood pressure, especially in individuals with hypertension. In addition, sodium reduction reduced albuminuria in patients with stage 1‐3 chronic kidney disease. Examination of the time course of blood pressure responses to sodium reduction revealed lowering sodium in the context of an average American diet may not produce maximal blood pressure reductions within a 4‐week intervention period. This review provides further evidence of the benefit of sodium reduction for blood pressure lowering and gives insights into the subgroups of the population that may derive the greatest benefit from sodium reduction and the time course required to see benefit. Only three high‐quality studies were identified during this 12‐month review period, highlighting the critical need for more well‐conducted rigorous studies in this area. 相似文献